← Evidence map

ReviewPharmaceuticals (Basel, Switzerland)2022

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.

Vishnu Eshwar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

28 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 36355537